GKT 831

Drug Profile

GKT 831

Alternative Names: GKT-137831; GKT-831

Latest Information Update: 08 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GenKyoTex
  • Developer GenKyoTex; University of California, Davis; University of California, San Diego
  • Class Anti-inflammatories; Antifibrotics; Antihyperglycaemics; Eye disorder therapies; Osteoporosis therapies; Pyrazoles; Pyridines; Skin disorder therapies; Small molecules; Vascular disorder therapies
  • Mechanism of Action NOX1 protein inhibitors; NOX4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis; Systemic scleroderma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Bile duct diseases; Diabetic nephropathies
  • No development reported Hepatic fibrosis; Idiopathic pulmonary fibrosis; Non-alcoholic steatohepatitis; Systemic scleroderma
  • Discontinued Atherosclerosis; Bone disorders; Eye-Disorders

Most Recent Events

  • 26 Sep 2018 GenKyoTex completes enrolment in its phase II trial for Bile duct diseases in USA, Canada, Belgium, Germany, Greece, Italy, Spain, the United Kingdom, and Israel (NCT03226067)
  • 03 Sep 2018 The independent Safety Monitoring Board (SMB) recommends continuation of a phase II trial in Bile duct diseases after second review meeting
  • 03 Sep 2018 Genkyotex plans an open label extension study for Bile duct diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top